Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
Session VII: MDS
Next Questions In High- and Low-Risk MDS Treatment
Thursday, May 12, 2022
12:55 PM – 1:15 PM
Speaker(s)
David Sallman, MD
Assistant Member, Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Learning Objectives:
Describe the importance of risk stratification in MDS and the differences in treatment goals for
low-risk and high-risk MDS subtypes
Appraise clinical trial data reporting on the efficacy of current and emerging therapies in low-risk
MDS
Evaluate clinical safety data on emerging second-line treatment options in high-risk MDS